CytomX Therapeutics, Inc. (CTMX) Institutional Ownership

Ownership Summary

CytomX Therapeutics, Inc. (NASDAQ:CTMX) currently has 103 active institutional owners and shareholders as of today (September 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).

• CytomX Therapeutics saw its institutional ownership percentage fell to 83.5% in September 2025 from 165.4% in June 2025.
• On a quarter-over-quarter basis, institutional holdings shifted by 12.70%, with a year-over-year an increase of 51.47% in the count of filers.
• During the quarter, 57 institutions bought more CytomX Therapeutics shares, 28 sold shares, and 18 of the 103 total investors held their position steady.
• The total number of shares held by institutions in CytomX Therapeutics increased to 137.75Mn as of September 2025, a net change of up by 15.52Mn shares quarter on quarter, and up 86.92Mn shares year over year.
• VR Adviser, LLC continues to be the largest institutional holder of CytomX Therapeutics as of September 30, 2025, with a position of 15.56Mn shares, representing 9.44% of the company's outstanding stock.
• Among the most significant buyers of CytomX Therapeutics during September 2025 were FMR LLC (6.16Mn), Ikarian Capital, LLC (3.36Mn), PERCEPTIVE ADVISORS LLC (2.69Mn), CITADEL ADVISORS LLC (1.80Mn), VR Adviser, LLC (1.59Mn).
• Leading sellers of CytomX Therapeutics stock in September 2025 included Point72 Asset Management, L.P. (4.02Mn), Prosight Management, LP (2.95Mn), Vivo Capital, LLC (2.88Mn), MARSHALL WACE, LLP (1.25Mn), ACADIAN ASSET MANAGEMENT LLC (903.31K).
• The top 10 institutional holders of CytomX Therapeutics for the quarter ending September 2025 included VR Adviser, LLC (15.56Mn), FMR LLC (15.40Mn), TANG CAPITAL MANAGEMENT LLC (11.07Mn), PERCEPTIVE ADVISORS LLC (9.68Mn), VANGUARD GROUP INC (8.95Mn), ORBIMED ADVISORS LLC (8.46Mn), Commodore Capital LP (7.69Mn), BAKER BROS. ADVISORS LP (4.25Mn), Point72 Asset Management, L.P. (4.07Mn), ADAR1 Capital Management, LLC (4.05Mn).